Overwhelming postsplenectomy infection: A prospective multicenter cohort study

Clinical Infectious Diseases

Volumn 62, Issue 7, 2016, Pages 871-878

  Theilacker, Christian ^a,g   Ludewig, Katrin ^b   Serr, Annerose ^a   Schimpf, Julia ^a   Held, Jürgen ^a,c   Bögelein, Martin ^a   Bahr, Viola ^b   Rusch, Stephan ^a   Pohl, Annette ^a   Kogelmann, Klaus ^d   Frieseke, Sigrun ^e   Bogdanski, Ralph ^f   Brunkhorst, Frank M ^b   Kern, Winfried V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d Klinikum Emden   (Germany)

^e UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

asplenia; overwhelming postsplenectomy infection; pneumococcal vaccine; splenectomy.; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ASPLENIA; BLOODSTREAM INFECTION; BODY MASS; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FULMINATING PURPURA; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERWHELMING POSTSPLENECTOMY INFECTION; PNEUMOCOCCAL INFECTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; ADVERSE EFFECTS; CLINICAL TRIAL; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PNEUMOCOCCAL INFECTIONS; POSTOPERATIVE COMPLICATIONS; STATISTICS AND NUMERICAL DATA; VACCINATION;

ADULT; AGED; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84963973461     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1195     Document Type: Conference Paper

References (31)

1. Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med. 2014; 371: 349-56.
2. Theilacker C, Kern WV. Prevention of sepsis after splenectomy [in German]. Dtsch Med Wochenschr. 2013; 138: 1729-33.
3. Edgren G, Almqvist R, Hartman M, Utter GH. Splenectomy and the risk of sepsis: a population-based cohort study. Ann Surg. 2014; 260: 1081-7.
4. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risks. Br J Surg. 1991; 78: 1031-8.
5. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect. 2001; 43: 182-6.
6. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011; 378: 86-97.
7. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012; 61: 816-9.
8. Robert Koch Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. August 2013. Epidemiologische Bulletin. 2013; 34: 313-44.
9. Engelhardt M, Eber SW, Germing U, Heimpel H, Kern WV, Schmugge M. Prävention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie. 2013: 1-29. Available at: http://www.dgho-onkopedia.de/de/onkopedia/.leitlinien/praevention-von-infektionen-und-Thrombosen-nach/pra-vention-voninfektionen-und-Thrombosen-nach.pdf. Accessed 23 March 2013.
10. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann Intern Med. 2009; 151: 546-55.
11. Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schønheyder HC, Sørensen HT. Risk and patterns of bacteraemia after splenectomy: a population-based study. Scand J Infect Dis. 2000; 32: 521-5.
12. Kyaw MH, Holmes EM, Toolis F, et al. Evaluation of severe infection and survival after splenectomy. Am J Med. 2006; 119: 276.e1-7.
13. Henriksen DP, Laursen CB, Jensen TG, Hallas J, Pedersen C, Lassen AT. Incidence rate of community-Acquired sepsis among hospitalized acute medical patients-A population-based survey. Crit Care Med. 2015; 43: 13-21.
14. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101: 1644-55.
15. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-Associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36: 309-32.
16. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead?. BMJ. 1998; 316: 989-91.
17. Zou G A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702-6.
18. Engel C, Brunkhorst FM, Bone H-G, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007; 33: 606-18.
19. Gonçalves-Pereira J, Povoa PR, Lobo C, Carneiro AH. Bloodstream infections as a marker of community-Acquired sepsis severity. Results from the Portuguese community-Acquired sepsis study (SACiUCI study). Clin Microbiol Infect. 2013; 19: 242-8.
20. MacNeil JR, Cohn AC, Farley M, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease-United States, 1989-2008. Clin Infect Dis. 2011; 53: 1230-6.
21. Kyaw MH, Holmes EM, Chalmers J, Jones IG, Campbell H A survey of vaccine coverage and antibiotic prophylaxis in splenectomised patients in Scotland. J Clin Pathol. 2002; 55: 472-4.
22. Omlin AG, Mühlemann K, Fey MF, Pabst T. Pneumococcal vaccination in splenectomised cancer patients. Eur J Cancer. 2005; 41: 1731-4.
23. Meerveld-Eggink A, de Weerdt O, Rijkers GT, van Velzen-Blad H, Biesma DH. Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in the Netherlands. Vaccine. 2008; 26: 6975-9.
24. Theidel U, Kuhlmann A, Braem A. Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850, 000 individuals. Dtsch Arztebl Int. 2013; 110: 743-50.
25. Cherif H, Landgren O, Konradsen HB, Kalin M, Björkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine. 2006; 24: 75-81.
26. Davis MDP, Dy KM, Nelson S. Presentation and outcome of purpura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. J Am Acad Dermatol. 2007; 57: 944-56.
27. Zerbib P, Patenotre P, Chambon JP. Purpura fulminans in an asplenic patient. Br J Haematol. 2007; 139: 171.
28. Wojtowicz JM, Longden Jones G. Streptococcus pneumoniae-induced purpura fulminans in a woman with functional asplenia. CJEM. 2014; 16: 339-42.
29. Vincent J-L, Nadel S, Kutsogiannis DJ, et al. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care. 2005; 9: R331-43.
30. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for proteinconjugate pneumococcal vaccine in adults: what is the supporting evidence?. Clin Infect Dis. 2011; 52: 633-40.
31. Bonten MJM, Bolkenbaas M, Patterson S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372: 1114-25.